British-Swedish group AstraZeneca has announced today its Q2 2018 financial results, which have satisfied investors and boosted the group’s shares, which have increased 3.8% (London). Investors were convinced by positive results from the most recent treatments – sales of new medicines have increased by 75%. This has offset the revenue loss by the most mature drugs, whose patent has expired––such as Crestor.
AstraZeneca’s revenues increased by 2% at constant exchange rates in Q2 2018, while EBIT decreased by 17% and net income decreased by 1%. The oncology sector was up 40% ($2.7bn) and has now a propelling role in the group, as it already accounts for one fifth of its total sales volume, thanks to products such as Lynparza, Tagrisso and Imfinzi.